UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 001-36288 Akari Therapeutics, Plc (Exact name of Registrant as specified in its Charter) England and Wales ...

Exhibit 99.1 Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio's ADC Cancer Therapeutic Platform Technology and Akari's PAS-nomacopan for Geographic Atrophy Existing Investors Support the Company with Issuance of $1 Million in Unsecured Convertible Notes Secured $7.6 Million in Upsized Financing Round Receives Positive a ...

Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan for Geographic Atrophy Existing Investors Support the Company with Issuance of $1 Million in Unsecured Convertible Notes Secured $7.6 Million in Upsized Financing Round Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy ...

BOSTON and LONDON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics announced today that the company has received positive and constructive Pre-IND (PIND) feedback from the FDA on July 29, 2024, which provides additional clarity on Akari’s final Investigational New Drug Application (IND)- enabling preclinical plans, drug manufacturing and Phase 1 clinical strategy for long-acting PAS-nomacopan for intravitreal treatment of geographic atrophy (GA). PAS-nomacopan is a long-acting bispecific inhibitor of C ...

Core Viewpoint - Akari Therapeutics Plc has successfully closed an initial private placement financing round, raising approximately $7.6 million from both new and existing investors, reflecting strong investor interest in the company's strategic direction and upcoming merger with Peak Bio [1][2]. Financing Details - The private placement agreement was finalized on May 29, 2024, involving the sale of 4,029,754 unregistered American Depository Shares (ADSs) and Series C Warrants at a unit price of $1.885 [2]. - The warrants have a three-year term and cashless exercise provisions, with an exercise price of $1.76 per ADS for most investors, while Dr. Ray Prudo and Samir R. Patel, M.D., have a slightly higher exercise price of $1.79 per ADS [2]. Proceeds and Issuance - As of the initial closing on May 31, 2024, the company received gross proceeds of approximately $7.2 million, issuing 3,817,553 unregistered ADSs and warrants [3]. - The remaining 212,201 ADSs and warrants are expected to be issued within 90 days of May 31, 2024, pending payment [3]. Company Overview - Akari Therapeutics is focused on developing advanced therapies for autoimmune and inflammatory diseases, with its lead asset being investigational nomacopan, a bispecific recombinant inhibitor targeting complement C5 activation and leukotriene B4 activity [5].

Exhibit 99.1 Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio's ADC Cancer Therapeutic Platform Technology and Akari's PAS-nomacopan for Geographic Atrophy Implementation of Restructuring Plan to Reduce Operating Costs Existing Investors Support the Company with Issuance of $1 million in Unsecured Convertible Notes BOSTON and LONDON, May 16, 2024 (GLOBE NEWSWIRE) – Akari The ...

Core Viewpoint - Akari Therapeutics has entered into a definitive merger agreement with Peak Bio, expected to close in the third quarter of 2024, with a focus on advancing their respective therapeutic technologies and restructuring to reduce operating costs [1][3][7]. Company Highlights - The merger with Peak Bio will be an all-stock transaction, resulting in a combined entity operating as Akari Therapeutics, Plc, continuing to trade on Nasdaq as AKTX [3][7]. - The leadership has changed with Samir R. Patel, M.D. appointed as interim CEO following the departure of Rachelle Jacques [3]. - A significant reduction in workforce of approximately 67% has been initiated as part of an operational restructuring plan to lower costs [3]. - Existing investors have supported the company with the issuance of $1 million in unsecured convertible notes [1]. Financial Results - As of March 31, 2024, the company reported cash of approximately $1.3 million [4][18]. - Research and development expenses increased to approximately $2.3 million for Q1 2024, compared to $1.7 million in Q1 2023 [4][17]. - General and administrative expenses rose to approximately $3.7 million for Q1 2024, up from $2.9 million in Q1 2023 [4][17]. - The net loss for Q1 2024 was approximately $5.6 million, a significant decline from a net income of approximately $1.0 million in Q1 2023 [5][6][17]. - The weighted-average number of ordinary shares used in computing net loss per share was approximately 13.45 billion for Q1 2024, compared to 7.47 billion for Q1 2023 [17]. Merger Details - The merger agreement stipulates that Peak stockholders will receive Akari shares based on an exchange ratio, leading to an implied equity ownership of approximately 50% for both Akari and Peak stockholders [7]. - The transaction is subject to customary closing conditions, including shareholder approval from both companies [7].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 001-36288 Akari Therapeutics, Plc (Exact name of Registrant as specified in its Charter) England and Wales ...

BOSTON and LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will present new pre-clinical data on investigational long-acting PAS-nomacopan including drug effect on electroretinography (ERG) testing in a blue light model at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle. Akari Chief Scientific Off ...

BOSTON and LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will present new pre-clinical data on investigational long-acting PAS-nomacopan including drug effect on electroretinography (ERG) testing in a blue light model at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle. Akari Chief Scientific Of ...